Alberto Ramirez Lopez, MD
Urology · Dorado, PRNPI 1437134897
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,100 of the $46,667 with a category attached, or 90.2%. Verity Pharmaceuticals Inc. accounts for 65.4% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $30,363, 3.3 times the $9,216 reported in 2019. Among urology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $765.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Verity Pharmaceuticals Inc.$31K
- AbbVie$14K
- Neotract Inc.$840
- Johnson & Johnson$332
- Pfizer$165
- Olympus Latin America, Inc.$130
- plus $618 from 7 others
What the payments were for
- Speaking & faculty fees$42,10090%
- Travel & lodging$1,8614%
- Food & beverage$2,3955%
- Education$3111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Verity Pharmaceuticals Inc. | 11 | $30,543 |
| AbbVie(2 entities) | 24 | $14,039 |
| Neotract Inc. | 5 | $840 |
| Johnson & Johnson(2 entities) | 8 | $332 |
| Pfizer | 3 | $165 |
| Olympus Latin America, Inc. | 1 | $130 |
| Boston Scientific | 2 | $124 |
| Progenics Pharmaceuticals, Inc. | 1 | $124 |
| Travere Therapeutics, Inc. | 2 | $118 |
| Novo Nordisk | 1 | $111 |
| Merck | 1 | $100 |
| Tolmar, Inc. | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,667 in reported general payments places this provider in the 90th percentile of 122 urology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 43 | $614,018 |
| ErleadaApalutamide | 25 | $377,400 |
| TrelstarTriptorelin Pamoate | 106 | $119,905 |
| MyrbetriqMirabegron | 191 | $97,783 |
| Lupron DepotLeuprolide Acetate | 18 | $56,367 |
| Tamsulosin Hcl | 4,312 | $32,568 |
| PremarinEstrogens, Conjugated | 58 | $25,733 |
| EligardLeuprolide Acetate | 29 | $21,368 |
| Finasteride | 2,032 | $17,680 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 1,076 | $12,265 |
| Tolterodine Tartrate ErTolterodine Tartrate | 166 | $7,933 |
| Tadalafil | 95 | $6,372 |
| Bicalutamide | 176 | $4,623 |
| Oxybutynin Chloride ErOxybutynin Chloride | 269 | $4,266 |
| Sildenafil Citrate | 205 | $4,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $332 | $377,40025 claims |
| Verity Pharmaceuticals Inc.Trelstar | $30,543 | $119,905106 claims |
| AbbVieLupron Depot | $14,039 | $56,36718 claims |
| PfizerPremarin | $165 | $25,73358 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 122 urology providers in Puerto Rico.
Other urology in Dorado
- Claudio Bernaschina BobadillaPonce$132K
- Mariela Martinez-RiveraPonce$105K
- Freddy Mendez TorresCayey$95K
- Luis AmbertRio Piedras$64K
- Jorge Crespo CarrilloRio Piedras$62K
- Ronald Cadillo ChavezBayamon$61K
- Andres Perez RomanSan Juan$58K
- Rafael Bouet BlasiniSan Juan$55K
- Antonio Yulian ValentinCaguas$48K
- Jose Saavedra-BelaundeSan Juan$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.